https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=16254
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=16254
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADSofosbuvir / Velpatasvir may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.
–
–
–
Possible increased risk of HMG CoA inhibitor toxicity.
Start with a small dosage. Monitor closely for signs and symptoms of toxicity and adjust dosage as a function of efficacy and tolerance.
We do not recommend more than 10 mg per day.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
CK
ALT
AST
Lipidic profile
| Reference number |
|---|
| # patients |
| HCV |
| Dose |
| Frequency |
| AUC |
| Cmax |
| 3250 |
|---|
| 18 |
| - |
| 100 mg * |
| QD |
| 3250 |
|---|
| 18 |
| - |
| 20 mg |
| x 1 |
| + 169% (2.7x) |
| + 161% (2.6x) |
Ref #3250 : * This study was conducted with velpatasvir alone but no significant interaction is anticipated with sofosbuvir. The effects on velpatasvir have not been studied but no significant change is anticipated.